Online First

The following Cholangiocarcinoma News articles are now available online ahead of print.

Important Role of Screening for Genomic Alterations in Cholangiocarcinoma

September/October 2021, Vol 2, No 3 — October 7, 2021

Comprehensive molecular profiling has demonstrated a diverse landscape of oncogenic genomic alterations in cholangiocarcinoma (CCA), which are often the drivers of CCA. In a recent review article, Tanios S. Bekaii-Saab, MD, FACP, Vice Chair and Section Chief for Medical Oncology, Department of Internal Medicine, Mayo Clinic Cancer Center, Phoenix, AZ, and colleagues provided an overview of the molecular heterogeneity of CCA, discussing the role of molecular tests for the diagnosis of patients with intrahepatic CCA, and the implications of the genomic alterations in the treatment of patients with this aggressive disease.

Online First

Navigating Compassionate Use Options for Your Patients with Cholangiocarcinoma

By Melinda Bachini

CCF Corner

September/October 2021, Vol 2, No 3 — October 7, 2021

I believe that the most powerful and positive force in medicine is that of a self-advocating patient. At the Cholangiocarcinoma Foundation, we strive to connect, educate, and empower patients with cholangiocarcinoma (CCA) to partner with their care team in navigating the course of their treatment. However, we understand that the treatment options are extremely limited for many patients with CCA.

Online First

National Survey Pinpoints Reasons Oncologists Do Not Order Molecular Testing

In the Literature

September/October 2021, Vol 2, No 3 — October 7, 2021

Multimarker tumor panel testing is beneficial in helping to inform treatment choice in precision oncology. However, little is known about the clinic-based and organizational factors related to multimarker tumor panel testing, and why oncologists may not choose this testing.

Online First

Role of Intraductal Treatment and Endoscopic Oncologists in the Management of Unresectable Extrahepatic Cholangiocarcinoma

Cholangiocarcinoma, In the Literature

September/October 2021, Vol 2, No 3 — October 7, 2021

Although cholangiocarcinoma (CCA) is a rare cancer that originates in the bile ducts, its incidence rate continues to rise in the United States, and many patients are diagnosed late, with unresectable tumor and poor prognosis. The majority of patients with extrahepatic CCA, including the perihilar subtype, require referral to a center with expertise in endoscopic retrograde cholangiopancreatography (ERCP) and interventional radiology, because of the complexities in obtaining a definitive diagnosis and durable biliary drainage.

Online First

Incorporating FGFR Inhibitors into the Treatment Paradigm for Cholangiocarcinoma: Current Concepts and Future Directions

By Mitesh J. Borad, MD; Milind M. Javle, MD; Michael Morse, MD, FACP, MHS; Lewis R. Roberts, MB, ChB, PhD

Cholangiocarcinoma, Continuing Education

June/July 2021, Vol 2, No 2 — June 29, 2021

On January 15, 2021, experts in the management of patients with cholangiocarcinoma (CCA) convened for a virtual accredited continuing education satellite symposium held during the 2021 annual meeting of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. The goal was to educate healthcare providers on various aspects of CCA, including epidemiology, current standards of care, unmet clinical needs, the safety and efficacy of fibroblast growth factor receptor (FGFR) inhibitors as second-line therapy, and practical approaches to incorporating FGFR inhibitors into the treatment paradigm for the disease.

Online First

Subscribe to CCA News

I'd like to receive:

Stay In The Know